GlassScriptPhysician profile
Lenin Pinnamaneni
NPI 1871595819
$7,137.91
in general payments reported to CMS, 2019-2025
32 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $747 · 2021: $1,141 · 2022: $968 · 2023: $825 · 2024: $1,197 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,047.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $875.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $769.45 | 2019-2025 | Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $618.22 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $542.40 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $464.45 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $345.01 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.10 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $264.88 | 2020-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $245.96 | 2023-2025 | Rexulti |
| Pfizer INC. | $241.36 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $205.09 | 2019-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $179.86 | 2019-2022 | |
| Amgen INC. | $172.37 | 2019-2021 | |
| Mylan Specialty L.P. | $129.59 | 2021-2024 | Yupelri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $111.71 | 2019 | |
| Dexcom, INC. | $85.89 | 2024-2025 | Dexcom G6 Transmitter |
| Intuitive Surgical, INC. | $74.60 | 2019 | |
| Viatris Specialty LLC | $56.89 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $56.39 | 2019 | |
| Corcept Therapeutics | $52.04 | 2025 | Korlym |
| Medtronic, INC. | $50.00 | 2024 | Abre |
| Biogen, INC. | $36.30 | 2021 | |
| Xeris Pharmaceuticals, INC. | $34.64 | 2024-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $24.88 | 2023 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $23.51 | 2020 | |
| Tactile Systems Technology INC | $23.51 | 2024 | Flexitouch Plus, Entre Plus |
| Amneal Pharmaceuticals LLC | $23.34 | 2024 | Rytary |
| Shield Therapeutics INC | $20.47 | 2024 | |
| Abbott Laboratories | $20.45 | 2025 | Freestyle Libre 3 |
| Abbvie INC. | $16.91 | 2022 | |
| Radius Health, INC. | $14.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenin Pinnamaneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.